Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
3/24/2026, 12:00:00 AM
Regeneron and Sanofi announced Dupixent's approval in Japan for bullous pemphigoid on March 24, 2026; <5% impact estimated due to niche market expected.
Korean Translation
2026년 3월 24일 리제네론과 사노피의 듀피젠트가 일본에서 수포성 유사천포창 치료제로 승인되었으며, 틈새 시장 특성상 5% 미만의 주가 영향이 예상됨.
Related Recent Events
Hewlett Packard Enterprise Co (HPE) · Other
HPE Discover Las Vegas 2026, the company's flagship annual event, is scheduled to begin, running from June 15-18. Major announcements on AI, cloud, and networking are anticipated to drive market interest scheduled.
6/15/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Fiscal Q2 2026 earnings release is expected. The company guided for revenue between $9.6 billion and $10.0 billion and non-GAAP EPS between $0.51 and $0.55. High volatility is anticipated based on historical earnings reactions expected.
6/2/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q1 2026 earnings release scheduled for 2026-05-20 scheduled.
5/20/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
2026 Annual Meeting of Shareholders, which is expected to have low impact as a standard meeting, is scheduled.
5/20/2026, 12:00:00 AM